安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Corcept Therapeutics
Corcept advances cortisol modulation therapies to treat serious diseases Learn more about our research, innovation, and commitment to better health
- Pipeline and Clinical Trials - Corcept Therapeutics
Learn more about the design and status of current Corcept-sponsored clinical trials and find contact information for investigators
- Investor Relations – Corcept Therapeutics, Incorporated
The Investor Relations website contains information about Corcept Therapeutics, Incorporated's business for stockholders, potential investors, and financial analysts
- About - Corcept Therapeutics
Discover Corcept Therapeutics, pioneering cortisol modulation therapies to meet critical patient needs through science and collaboration
- Products - Corcept Therapeutics
View information about the Corcept Access Financial Support and Patient Advocate Program for Korlym To report a medical adverse event, side effect, or a product complaint, please call 1-855-844-3270
- Cortisol Modulation - Corcept Therapeutics
Cortisol modulation may have the potential to treat a variety of serious diseases directly affected by cortisol dysregulation Our decades of extensive research indicate that modulating cortisol’s activity at the glucocorticoid receptor (GR) may provide pathways for treating serious diseases The binding of cortisol to the GR increases the expression of some genes and reduces others With
- FDA Files Corcept’s New Drug Application for Relacorilant as Treatment . . .
“The FDA’s acceptance of our New Drug Application takes us another step closer to bringing relacorilant to patients with hypercortisolism,” said Joseph Belanoff, M D , Corcept’s Chief Executive Officer
- Corcept Submits New Drug Application for Relacorilant as a Treatment . . .
Corcept’s NDA is based on positive results from the pivotal GRACE trial and confirmatory evidence from the Phase 3 GRADIENT and long-term extension studies and a Phase 2 study in hypercortisolism Patients in these studies who received relacorilant experienced improvements in a wide array of hypercortisolism’s signs and symptoms, with an acceptable safety burden Notably, there were no
|
|
|